Tara Bancroft
Stock Analyst at TD Cowen
(2.51)
# 2,347
Out of 5,240 analysts
11
Total ratings
66.67%
Success rate
11.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tara Bancroft
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MLYS Mineralys Therapeutics | Initiates: Buy | n/a | $26.86 | - | 1 | Apr 27, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $90 → $100 | $103.88 | -3.74% | 2 | Feb 26, 2026 | |
| OCUL Ocular Therapeutix | Maintains: Buy | $14 → $20 | $9.24 | +116.45% | 4 | Oct 30, 2025 | |
| LNTH Lantheus Holdings | Maintains: Buy | $95 → $80 | $96.46 | -17.06% | 1 | Sep 15, 2025 | |
| TGTX TG Therapeutics | Initiates: Buy | $50 | $42.65 | +17.23% | 1 | Oct 29, 2024 | |
| GERN Geron | Initiates: Buy | $10 | $1.41 | +609.22% | 1 | Apr 29, 2024 | |
| BCYC Bicycle Therapeutics | Initiates: Outperform | n/a | $4.74 | - | 1 | Aug 31, 2022 |
Mineralys Therapeutics
Apr 27, 2026
Initiates: Buy
Price Target: n/a
Current: $26.86
Upside: -
Protagonist Therapeutics
Feb 26, 2026
Maintains: Buy
Price Target: $90 → $100
Current: $103.88
Upside: -3.74%
Ocular Therapeutix
Oct 30, 2025
Maintains: Buy
Price Target: $14 → $20
Current: $9.24
Upside: +116.45%
Lantheus Holdings
Sep 15, 2025
Maintains: Buy
Price Target: $95 → $80
Current: $96.46
Upside: -17.06%
TG Therapeutics
Oct 29, 2024
Initiates: Buy
Price Target: $50
Current: $42.65
Upside: +17.23%
Geron
Apr 29, 2024
Initiates: Buy
Price Target: $10
Current: $1.41
Upside: +609.22%
Bicycle Therapeutics
Aug 31, 2022
Initiates: Outperform
Price Target: n/a
Current: $4.74
Upside: -